TABLE A1.
Variation in the effects of cohort (age at interview) in predicting lifetime risk of DSM‐V/CIDI disorders in Qatar.
Disorder category | Age cohort | Sub‐samples | |||||
---|---|---|---|---|---|---|---|
Early | Middle | Late | |||||
OR | 95% CI | OR | 95% CI | OR | 95% CI | ||
Panic disorder | 18–29 | 14.8* | (5.3–41.8) | ‐ | ‐ | ‐ | ‐ |
30–39 | 5.8* | (2.1–15.7) | 16.1* | (4.1–63.1) | ‐ | ‐ | |
40–49 | 2.3 | (0.8–6.7) | 2.7 | (0.8–8.7) | 2.4 | (0.5–11.0) | |
50+ | 1.0 | ‐‐ | 1.0 | ‐‐ | 1.0 | ‐‐ | |
Test statistics | F3,48 (PF) | 16.2 (<0.001)* | F2,49 (PF) | 11.9 (<0.001)* | F1,50 (PF) | 1.3 (0.251) | |
Generalized anxiety disorder | 18–29 | 11.2* | (5.6–22.2) | ‐ | ‐ | ‐ | ‐ |
30–39 | 4.2* | (2.0–9.0) | 7.4* | (3.1–17.3) | ‐ | ‐ | |
40–49 | 1.8 | (0.8–3.8) | 3.3* | (1.7–6.5) | 1.0 | (0.3–4.1) | |
50+ | 1.0 | ‐‐ | 1.0 | ‐‐ | 1.0 | ‐‐ | |
Test statistics | F3,48 (PF) | 36.2 (<0.001)* | F2,49 (PF) | 10.8 (<0.001)* | F1,50 (PF) | 0.0 (0.948) | |
PCL‐SC PTSD a | 18–29 | 5.1* | (2.8–9.3) | 6.2* | (3.5–11.2) | ‐ | ‐ |
30–39 | 2.0* | (1.2–3.4) | 4.8* | (3.1–7.6) | 5.0* | (2.0–12.3) | |
40–49 | 1.3 | (0.7–2.3) | 3.0* | (1.9–4.7) | 2.0* | (1.0–3.8) | |
50+ | 1.0 | ‐‐ | 1.0 | ‐‐ | 1.0 | ‐‐ | |
Test statistics | F3,48 (PF) | 22.0 (<0.001)* | F3,48 (PF) | 19.3 (<0.001)* | F2,49 (PF) | 6.7 (0.003)* | |
Obsessive‐compulsive disorder a | 18–29 | 6.1* | (2.1–17.7) | 3.3 | (0.7–16.2) | ‐ | ‐ |
30–39 | 4.6* | (1.7–12.1) | 5.2* | (1.8–15.4) | 4.0 | (0.3–57.0) | |
40–49 | 1.4 | (0.5–4.3) | 1.4 | (0.3–6.0) | 1.3 | (0.4–4.6) | |
50+ | 1.0 | ‐‐ | 1.0 | ‐‐ | 1.0 | ‐‐ | |
Test statistics | F3,48 (PF) | 7.3 (<0.001)* | F3,48 (PF) | 4.3 (0.009)* | F2,49 (PF) | 0.5 (0.586) | |
Any anxiety disorders a | 18–29 | 5.9* | (3.3–10.6) | 4.1* | (2.3–7.5) | ‐ | ‐ |
30–39 | 2.6* | (1.5–4.6) | 3.5* | (2.3–5.4) | 5.2* | (2.4–11.3) | |
40–49 | 1.4 | (0.8–2.6) | 2.2* | (1.4–3.3) | 2.1* | (1.3–3.6) | |
50+ | 1.0 | ‐‐ | 1.0 | ‐‐ | 1.0 | ‐‐ | |
Test statistics | F3,48 (PF) | 29.0 (<0.001)* | F3,48 (PF) | 13.3 (<0.001)* | F2,49 (PF) | 10.7 (<0.001)* | |
Major depressive disorder | 18–29 | 29.5* | (14.4–60.5) | 6.1* | (2.3–16.1) | ‐ | ‐ |
30–39 | 9.2* | (4.4–19.2) | 3.8* | (2.4–5.9) | 16.8* | (6.3–45.2) | |
40–49 | 2.6* | (1.1–6.0) | 3.0* | (1.7–5.4) | 2.5* | (1.3–4.7) | |
50+ | 1.0 | ‐‐ | 1.0 | ‐‐ | 1.0 | ‐‐ | |
Test statistics | F3,48 (PF) | 87.1 (<0.001)* | F3,48 (PF) | 13.9 (<0.001)* | F2,49 (PF) | 16.8 (<0.001)* | |
Broad bipolar disorder | 18–29 | 7.5* | (3.8–14.6) | 3.9* | (1.7–9.1) | ‐ | ‐ |
30–39 | 4.0* | (2.1–7.7) | 4.5* | (2.4–8.4) | 2.3 | (1.0–5.3) | |
40–49 | 3.4* | (1.6–7.1) | 2.7* | (1.3–5.8) | 1.3 | (0.6–2.7) | |
50+ | 1.0 | ‐‐ | 1.0 | ‐‐ | 1.0 | ‐‐ | |
Test statistics | F3,48 (PF) | 16.1 (<0.001)* | F3,48 (PF) | 7.3 (<0.001)* | F2,49 (PF) | 2.6 (0.088) | |
Any mood disorders | 18–29 | 18.2* | (11.4–29.0) | 6.9* | (4.2–11.3) | ‐ | ‐ |
30–39 | 5.9* | (3.7–9.5) | 5.3* | (3.4–8.4) | 3.9* | (2.3–6.5) | |
40–49 | 3.1* | (1.9–5.3) | 3.0* | (1.9–4.7) | 2.1* | (1.4–3.4) | |
50+ | 1.0 | ‐‐ | 1.0 | ‐‐ | 1.0 | ‐‐ | |
Test statistics | F3,48 (PF) | 140.3 (<0.001)* | F3,48 (PF) | 25.0 (<0.001)* | F2,49 (PF) | 15.7 (<0.001)* | |
Any disorders a | 18–29 | 7.4* | (4.5–12.2) | 4.5* | (2.6–7.6) | ‐ | ‐ |
30–39 | 3.0* | (1.8–5.1) | 3.7* | (2.5–5.4) | 3.2* | (1.7–6.2) | |
40–49 | 1.8* | (1.1–3.1) | 2.1* | (1.4–3.2) | 1.9* | (1.2–3.2) | |
50+ | 1.0 | ‐‐ | 1.0 | ‐‐ | 1.0 | ‐‐ | |
Test statistics | F3,48 (PF) | 48.3 (<0.001)* | F3,48 (PF) | 19.7 (<0.001)* | F2,49 (PF) | 7.5 (0.001)* |
Note: Results reflect weighted person‐year level data. Models include time intervals and gender as controls. Categorization of person‐years into early, middle, and late sub‐samples was based on cut‐points at the projected 33rd and 67th percentiles of onset risk for each mental disorder (Panic Disorder: 30/44; Generalized Anxiety Disorder: 28/43; PCL‐SC PTSD: 22/33; Obsessive‐Compulsive Disorder: 21/37; Any Anxiety Disorders: 21/33; Major Depressive Disorder: 25/36; Broad Bipolar Disorder: 20/28; Any Mood Disorders: 23/33; Any Disorders: 21/32). ‐ Excluded from the analysis because there were no person‐years from the age cohort with the disorder in the sub‐sample.
Disorder was only assessed in the Part 2 sample (n = 2583).
*Significant age difference at the 0.05 level. *p < 0.05.